110 related articles for article (PubMed ID: 38879555)
1. Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons.
Makabe K; Okada H; Tachibana N; Ishikura H; Ito N; Tanaka M; Chijimatsu R; Terashima A; Yano F; Asaka M; Yanagihara D; Taketomi S; Matsumoto T; Tanaka S; Omata Y; Saito T
Arthritis Res Ther; 2024 Jun; 26(1):121. PubMed ID: 38879555
[TBL] [Abstract][Full Text] [Related]
2. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
3. The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells.
Weston S; Macdonald JL; Williams LM; Roussou E; Kang NV; Kiriakidis S; Taylor PC
Clin Exp Rheumatol; 2022 Sep; 40(9):1620-1628. PubMed ID: 34665696
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.
Dang C; Lu Y; Chen X; Li Q
Front Immunol; 2021; 12():650708. PubMed ID: 33927721
[TBL] [Abstract][Full Text] [Related]
5. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
[TBL] [Abstract][Full Text] [Related]
6. Red nucleus interleukin-1β evokes tactile allodynia through activation of JAK/STAT3 and JNK signaling pathways.
Guo YJ; Li HN; Ding CP; Han SP; Wang JY
J Neurosci Res; 2018 Dec; 96(12):1847-1861. PubMed ID: 30216497
[TBL] [Abstract][Full Text] [Related]
7. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
8. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
[TBL] [Abstract][Full Text] [Related]
10. Baricitinib relieves DSS-induced ulcerative colitis in mice by suppressing the NF-κB and JAK2/STAT3 signalling pathways.
Wu Q; Liu Y; Liang J; Dai A; Du B; Xi X; Jin L; Guo Y
Inflammopharmacology; 2024 Feb; 32(1):849-861. PubMed ID: 38227095
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
13. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
14. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
15. Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Harigai M; Honda S
Drugs; 2020 Aug; 80(12):1183-1201. PubMed ID: 32681420
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
18. Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Molet J; Mauborgne A; Diallo M; Armand V; Geny D; Villanueva L; Boucher Y; Pohl M
J Neurochem; 2016 Jan; 136(1):133-47. PubMed ID: 26440453
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Mitchell TS; Moots RJ; Wright HL
Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
[TBL] [Abstract][Full Text] [Related]
20. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]